About Crescendo Bioscience
Crescendo Bioscience is a company based in San Francisco (United States) founded in 2002 was acquired by Myriad Genetics in February 2014.. Crescendo Bioscience has raised $122.05 million across 4 funding rounds from investors including Kleiner Perkins, Myriad Genetics and HHS. The company has 128 employees as of December 31, 2022. Crescendo Bioscience operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
- Headquarter San Francisco, United States
- Employees 128 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Crescendo Bioscience Llc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$122.05 M (USD)
in 4 rounds
-
Latest Funding Round
$28.45 M (USD), Series D
Dec 31, 2012
-
Investors
Kleiner Perkins
& 6 more
-
Employee Count
128
as on Dec 31, 2022
-
Acquired by
Myriad Genetics
(Feb 04, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Crescendo Bioscience
Crescendo Bioscience has successfully raised a total of $122.05M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $28.45 million completed in December 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series D — $28.5M
-
First Round
First Round
(23 Oct 2008)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2012 | Amount | Series D - Crescendo Bioscience | Valuation | Skyline Ventures | |
| Jun, 2011 | Amount | Series C - Crescendo Bioscience | Valuation | Calibrium , Mohr Davidow Ventures |
|
| Jul, 2010 | Amount | Series C - Crescendo Bioscience | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Crescendo Bioscience
Crescendo Bioscience has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, Myriad Genetics and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US life sciences companies are invested in by Skyline Ventures.
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in early and growth stage companies
|
Founded Year | Domain | Location | |
|
Venture capital investments are managed in technology and healthcare sectors by this firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Crescendo Bioscience
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Crescendo Bioscience
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Crescendo Bioscience Comparisons
Competitors of Crescendo Bioscience
Crescendo Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Digital sequencing technology for cancer detection is developed.
|
|
| domain | founded_year | HQ Location |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| domain | founded_year | HQ Location |
Genomics-based diagnostic tests for cancer are provided.
|
|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Health risks are identified through online genetic and diagnostic testing.
|
|
| domain | founded_year | HQ Location |
Genomics-based diagnostic tests for cancer are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Crescendo Bioscience
When was Crescendo Bioscience founded?
Crescendo Bioscience was founded in 2002 and raised its 1st funding round 6 years after it was founded.
Where is Crescendo Bioscience located?
Crescendo Bioscience is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Crescendo Bioscience a funded company?
Crescendo Bioscience is a funded company, having raised a total of $122.05M across 4 funding rounds to date. The company's 1st funding round was a Series C of $37.6M, raised on Oct 23, 2008.
How many employees does Crescendo Bioscience have?
As of Dec 31, 2022, the latest employee count at Crescendo Bioscience is 128.
What does Crescendo Bioscience do?
Crescendo Bioscience was founded in 2002 in San Francisco, United States, as a CLIA-certified laboratory in the biotechnology sector. Molecular diagnostic tests are offered to support management of patients with autoimmune and inflammatory conditions. The Vectra DA assay, which evaluates 12 biomarkers for rheumatoid arthritis, is utilized to measure disease activity and predict therapy responses. Acquisition by Myriad Genetics occurred in February 2014 for 270 million.
Who are the top competitors of Crescendo Bioscience?
Crescendo Bioscience's top competitors include Guardant Health, Exact Sciences and Foundation Medicine.
Who are Crescendo Bioscience's investors?
Crescendo Bioscience has 7 investors. Key investors include Kleiner Perkins, Myriad Genetics, HHS, Safeguard Scientifics, and Skyline Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.